See more : Parrot SA (PABSB.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Sagittarius Life Science Corp (3205.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sagittarius Life Science Corp, a leading company in the Biotechnology industry within the Healthcare sector.
- Avarga Limited (U09.SI) Income Statement Analysis – Financial Results
- Algoma Central Corporation (AGMJF) Income Statement Analysis – Financial Results
- Pan American Energy Corp. (PNRG.CN) Income Statement Analysis – Financial Results
- Nemo Motors Corp (NMOC) Income Statement Analysis – Financial Results
- Crescera Capital Acquisition Corp. (CRECU) Income Statement Analysis – Financial Results
Sagittarius Life Science Corp (3205.TWO)
About Sagittarius Life Science Corp
Sagittarius Life Science Corp researches, develops, and sells Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 440.46M | 529.07M | 587.61M | 558.19M | 438.72M |
| Cost of Revenue | 368.98M | 446.50M | 487.07M | 448.32M | 369.61M |
| Gross Profit | 71.48M | 82.56M | 100.54M | 109.86M | 69.11M |
| Gross Profit Ratio | 16.23% | 15.61% | 17.11% | 19.68% | 15.75% |
| Research & Development | 21.83M | 22.69M | 31.58M | 24.86M | 28.58M |
| General & Administrative | 61.99M | 62.96M | 66.58M | 66.47M | 67.41M |
| Selling & Marketing | 52.03M | 79.14M | 92.40M | 90.33M | 78.22M |
| SG&A | 114.02M | 142.10M | 158.98M | 156.81M | 145.63M |
| Other Expenses | 0.00 | 7.46M | 1.68M | -4.73M | 0.00 |
| Operating Expenses | 135.85M | 164.79M | 190.55M | 181.67M | 174.20M |
| Cost & Expenses | 504.84M | 611.29M | 677.63M | 629.99M | 543.81M |
| Interest Income | 2.90M | 1.48M | 1.26M | 2.87M | 5.66M |
| Interest Expense | 82.00K | 234.00K | 388.00K | 330.00K | 246.00K |
| Depreciation & Amortization | 12.00M | 20.92M | 24.18M | 26.03M | 15.07M |
| EBITDA | -44.74M | -55.40M | -65.92M | -50.67M | -83.66M |
| EBITDA Ratio | -10.16% | -10.46% | -10.70% | -8.53% | -20.52% |
| Operating Income | -64.38M | -76.27M | -87.07M | -73.67M | -105.10M |
| Operating Income Ratio | -14.62% | -14.42% | -14.82% | -13.20% | -23.96% |
| Total Other Income/Expenses | 7.55M | -234.00K | 2.55M | -2.20M | -5.24M |
| Income Before Tax | -56.82M | -76.50M | -87.46M | -74.00M | -110.33M |
| Income Before Tax Ratio | -12.90% | -14.46% | -14.88% | -13.26% | -25.15% |
| Income Tax Expense | 0.00 | -12.00K | -1.04M | 488.00K | 9.66M |
| Net Income | -55.04M | -74.20M | -86.42M | -74.12M | -119.51M |
| Net Income Ratio | -12.50% | -14.02% | -14.71% | -13.28% | -27.24% |
| EPS | -1.69 | -2.28 | -2.66 | -2.27 | -3.65 |
| EPS Diluted | -1.69 | -2.28 | -2.66 | -2.27 | -3.65 |
| Weighted Avg Shares Out | 32.55M | 32.55M | 32.55M | 32.62M | 32.77M |
| Weighted Avg Shares Out (Dil) | 32.55M | 32.55M | 32.55M | 32.62M | 32.77M |
Source: https://incomestatements.info
Category: Stock Reports